Last reviewed · How we verify

NCT03673774: HPepic

Impedancemetry in Patients Monitored for Pulmonary Hypertension

Terminated NA Last updated 12 July 2023
What this trial tests

NA trial testing cardiac impedancemetry in Pulmonary Hypertension in 59 participants. Terminated before completion.

Timeline
23 August 2017
Primary endpoint
1 January 2021
1 January 2021

Quick facts

Lead sponsorUniversity Hospital, Toulouse
PhaseNA
StatusTerminated
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposeprevention
Enrollment59
Start date23 August 2017
Primary completion1 January 2021
Estimated completion1 January 2021
Sites1 location across France

Drugs / interventions tested

Conditions studied

Sponsor

University Hospital, Toulouse

Who can join

Adults 18 to 80, any sex, with Pulmonary Hypertension. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Monocentric cohort study, prospective, evaluating the variability of cardiac output measurement by resting and stress impedancemetry as a prognostic factor for Pulmonary Hypertension

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Pulmonary Hypertension

Currently open trials in the same condition.

Other University Hospital, Toulouse trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03673774.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing